The Tecnis PureSee IOL is the first FDA-approved extended depth of focus IOL maintaining contrast sensitivity comparable to ...

The TECNIS Odyssey IOL addresses a significant unmet need for cataract patients seeking greater spectacle independence., Bizz ...

The FDA approved the Tecnis PureSee IOL, an extended depth of focus IOL for cataract surgery, according to a press release ...

Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for both large-market as well as orphan ...

Cataracts are incredibly common among older adults. More than half of all Americans over age 80 either have cataracts or have had surgery to remove them. “They are a common eye condition where the ...

TECNIS PureSee IOL197% of patients would recommend this IOL to friends or family2TECNIS PureSee IOL is the first and only U.S ...

The TECNIS PureSee IOL addresses both cataract-related vision loss and presbyopia, which affects near vision as eyes age.

Johnson & Johnson (NYSE: JNJ) announced U.S. Food and Drug Administration (FDA) approval of TECNIS PureSee IOL, an extended depth of focus (EDOF) intraocular lens (IOL) intended for use in cataract ...

Johnson & Johnson’s TECNIS Odyssey IOL launched in India, offering a full visual range and high contrast to reduce spectacle ...

Johnson & Johnson introduces the TECNIS Odyssey IOL in India, enhancing vision for cataract patients with advanced technology.